Patient ‐reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia

CONCLUSIONSThe current PRO data support the favorable benefit/risk ratio of InO for the treatment of relapsed/refractory acute lymphoblastic leukemia, with superior clinical efficacy and better QoL. Cancer 2018. © 2018 American Cancer Society.

Source: Cancer - March 1, 2018 Category: Cancer & Oncology Authors: Hagop M. Kantarjian, Yun Su, Elias J. Jabbour, Helen Bhattacharyya, Eric Yan, Joseph C. Cappelleri, David I. Marks Tags: Original Article Source Type: research